Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors

Area of Science:

• Immunology
• Cancer Biology
• Metabolic Pathways

Background:

• CD73 (NT5E) produces adenosine, a key mediator of tumor immune evasion by suppressing immune cells like NK cells.
• Adenosine contributes to tumor progression and immune cell dysfunction within the tumor microenvironment.

Purpose of the Study:

• To engineer human NK cells to target the CD73-adenosine axis for cancer immunotherapy.
• To evaluate the efficacy of CD73-targeted NK cells in blocking adenosinergic metabolism and mediating tumor cell killing.

Main Methods:

• Engineering human NK cells to inhibit CD73 enzymatic activity.
• Utilizing a non-small-cell lung cancer model to assess NK cell function.
• Evaluating in vivo efficacy, tumor infiltration, and intratumoral activation of engineered NK cells.

Main Results:

• Engineered NK cells impaired cancer cell ATP uptake and adenosinergic metabolism.
• CD73-targeted NK cells recognized and killed tumor cells overexpressing CD73.
• In vivo studies demonstrated tumor arrest, enhanced NK cell infiltration, and activation in CD73+ tumors.

Conclusions:

• Engineered NK cells targeting CD73 offer a single-agent immunotherapy approach.
• This strategy combines antibody specificity, purinergic signaling blockade, and NK cell-mediated cytotoxicity.
• CD73-targeted NK cells show potent in vivo anti-tumor activity and promote a favorable immune microenvironment.